Coronavirus Information for the UC San Diego Community

Our leaders are working closely with federal and state officials to ensure your ongoing safety at the university. Stay up to date with the latest developments. Learn more.

Laucysteinamide A, a hybrid PKS/NRPS metabolite from a Saipan cyanobacterium, cf. Caldora penicillata

TitleLaucysteinamide A, a hybrid PKS/NRPS metabolite from a Saipan cyanobacterium, cf. Caldora penicillata
Publication TypeJournal Article
Year of Publication2017
AuthorsZhang C., Naman C.B, Engene N, Gerwick WH
JournalMarine Drugs
Date Published2017/04
Type of ArticleArticle
ISBN Number1660-3397
Accession NumberWOS:000404228300037
Keywordsagents; blue-green alga; brine shrimp; cyanobacteria; Cytotoxicity; laucysteinamide A; lyngbya-majuscula; marine; molecular networking; natural-products; thiazoline alkaloid

A bioactivity guided study of a cf. Caldora penicillata species, collected during a 2013 expedition to the Pacific island of Saipan, Northern Mariana Islands (a commonwealth of the USA), led to the isolation of a new thiazoline-containing alkaloid, laucysteinamide A (1). Laucysteinamide A is a new monomeric analogue of the marine cyanobacterial metabolite, somocystinamide A (2), a disulfide-bonded dimeric compound that was isolated previously from a Fijian marine cyanobacterium. The structure and absolute configuration of laucysteinamide A (1) was determined by a detailed analysis of its NMR, MS, and CD spectra. In addition, the highly bioactive lipid, curacin D (3), was also found to be present in this cyanobacterial extract. The latter compound was responsible for the potent cytotoxicity of this extract to H-460 human non-small cell lung cancer cells in vitro.

Short TitleMar. Drugs
Student Publication: 
Research Topics: